Trial Profile
A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole; Everolimus; Exemestane; Fulvestrant; Letrozole; Loperamide; Pertuzumab; Samotolisib; Tamoxifen; Trastuzumab
- Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 10 Oct 2023 Planned End Date changed from 20 Sep 2023 to 31 Dec 2024.
- 08 Aug 2022 Planned End Date changed from 28 Oct 2023 to 20 Sep 2023.
- 18 Feb 2022 Planned End Date changed from 28 Oct 2022 to 28 Oct 2023.